MiMedx Group has reported positive results from a study of its EpiFix, a dehydrated human amniotic membrane allograft, designed as a treatment for diabetic neurovascular foot ulcers. The controlled, randomized trial, which enrolled 80 ...
Tags: MiMedx Group, EpiFix, dehydrated human amniotic membrane allograft